Identifying mutations that affect treatment response in advanced breast cancer
Novel estrogen receptor mutations as a biomarker dictating therapy response in advanced endocrine-resistant estrogen receptor-positive breast cancer
This study is looking at how certain changes in estrogen receptors might affect how well treatments work for advanced breast cancer, and it hopes to help personalize therapy options for patients by identifying these changes in their tumors.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10954053 on NIH RePORTER |
What this research studies
This research investigates how specific mutations in estrogen receptors can influence the effectiveness of therapies for advanced estrogen receptor-positive breast cancer. By analyzing tumor samples from patients with treatment-resistant cancer, the study aims to identify novel mutations that may serve as biomarkers for predicting therapy response. The approach includes advanced sequencing techniques to characterize these mutations and their impact on treatment outcomes. Patients may benefit from a more personalized treatment strategy based on their unique tumor mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced estrogen receptor-positive breast cancer who have shown resistance to standard endocrine therapies.
Not a fit: Patients with early-stage breast cancer or those who do not have estrogen receptor-positive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced breast cancer who currently have limited responses to existing therapies.
How similar studies have performed: Previous research has shown success in identifying biomarkers for therapy response in breast cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Nayar, Utthara — Johns Hopkins University
- Study coordinator: Nayar, Utthara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.